Zoryl-M 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The synergistic action of these two agents provides effective glycemic control in patients inadequately managed by diet and exercise alone. Zoryl-M 2 Tablet PR is typically prescribed when monotherapy with either agent is insufficient, offering improved efficacy while potentially minimizing dose-related side effects. It is essential to monitor blood glucose levels regularly to adjust dosage and prevent hypoglycemia, a known risk associated with sulfonylureas. The medication should be used with caution in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and weight gain. Zoryl-M 2 Tablet PR should be administered as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring, under the supervision of a healthcare professional.